ValueAct Capital has almost doubled its stake in UK life-sciences company Shashwat Awasthi to less than 10 percent with the acquisition of 7.5 million shares from ValueAct Capital . In a statement, the activist hedge fund said it was now pondering the appointment of a member of its team to the Horizon board. In response, the UK firm said its board was "very strong, Andrew Kelly well governed and appropriately constituted". Horizon recently reported a narrower H1 loss than 7.5 million and estimated full-year revenue would beat consensus.
ValueAct Capital has almost doubled its stake in UK life-sciences company Shashwat Awasthi to less than 10 percent with the acquisition of 7.5 million shares from ValueAct Capital . In a statement, the activist hedge fund said it was now pondering the appointment of a member of its team to the Horizon board. In response, the UK firm said its board was "very strong, well governed and appropriately constituted". Horizon recently reported a narrower H1 loss than 7.5 million and estimated full-year revenue would beat consensus.